Literature DB >> 9038975

Fluid resuscitation with O2 vs. non-O2 carriers after 2 h of hemorrhagic shock in conscious hamsters.

H Kerger1, A G Tsai, D J Saltzman, R M Winslow, M Intaglietta.   

Abstract

Efficacy of a cell-free o-raffinose cross-linked and oligomerized hemoglobin (Hemo-link) solution in restoring macro- and microcirculatory conditions after 2 h of hemorrhagic shock (40 mmHg) was compared with conventional treatment with autologous whole blood, Ringer lactate (RL), and Dextran 70. Studies were conducted in the dorsal skinfold microcirculation of conscious hamsters. Initial infusion was equivalent to shed blood volume (SBV) for RL and 50% of SBV for remaining solutions. After 2 h all animals received blood at 50% of SBV. Vessel diameter, functional capillary density, microvascular red blood cell velocity, and flow were measured. Arteriolar, venular, and tissue PO2 were determined by phosphorescence decay. Systemic parameters included mean arterial blood pressure, heart rate, arterial blood gases, pH, and base excess. Autologous whole blood and Hemolink, but not Dextran 70 and RL, restored mean arterial blood pressure, systemic blood gas, and metabolic parameters. Tissue PO2 recovered to 40-50% with blood and Hemolink but remained significantly lower (10-15% of control) with Dextran 70 and RL. Initial volume replacement after shock with blood or Hemolink yields equivalent macro- and microhemodynamic improvements not attainable with non-O2-carrying plasma expanders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038975     DOI: 10.1152/ajpheart.1997.272.1.H525

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  [Treatment of hemorrhagic shock. New therapy options].

Authors:  W G Voelckel; A von Goedecke; D Fries; A C Krismer; V Wenzel; K H Lindner
Journal:  Anaesthesist       Date:  2004-12       Impact factor: 1.041

2.  Impairment of functional capillary density but not oxygen delivery in the hamster window chamber during severe experimental malaria.

Authors:  Judith Martini; Irene Gramaglia; Marcos Intaglietta; Henri C van der Heyde
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Microvascular experimental evidence on the relative significance of restoring oxygen carrying capacity vs. blood viscosity in shock resuscitation.

Authors:  Beatriz Y Salazar Vázquez; Reto Wettstein; Pedro Cabrales; Amy G Tsai; Marcos Intaglietta
Journal:  Biochim Biophys Acta       Date:  2008-05-04

Review 4.  Examining and mitigating acellular hemoglobin vasoactivity.

Authors:  Pedro Cabrales
Journal:  Antioxid Redox Signal       Date:  2012-10-11       Impact factor: 8.401

Review 5.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

6.  Delaying blood transfusion in experimental acute anemia with a perfluorocarbon emulsion.

Authors:  Pedro Cabrales; Juan Carlos Briceño
Journal:  Anesthesiology       Date:  2011-04       Impact factor: 7.892

7.  Effects of maleimide-polyethylene glycol-modified human hemoglobin (MP4) on tissue necrosis in SKH1-hr hairless mice.

Authors:  Ole Goertz; M H Kirschner; H Lilienfein; P Babilas; H U Steinau; C Andree; A Daigeler; A Stachon; H Homann; S Langer
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

8.  Ringer's lactate solution enhances the inflammatory response during fluid resuscitation of experimentally induced haemorrhagic shock in rats.

Authors:  Krzysztof Kusza; Mariusz Mielniczuk; Lukasz Krokowicz; Jacek B Cywiński; Maria Siemionow
Journal:  Arch Med Sci       Date:  2017-09-05       Impact factor: 3.318

Review 9.  Resuscitation After Hemorrhagic Shock in the Microcirculation: Targeting Optimal Oxygen Delivery in the Design of Artificial Blood Substitutes.

Authors:  Carlos Munoz; Federico Aletti; Krianthan Govender; Pedro Cabrales; Erik B Kistler
Journal:  Front Med (Lausanne)       Date:  2020-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.